Banseog note · 2026-10-26
A company building the operating system that links AI models and lab robots
Current stage · from public events · 2026-11-14
- R&D · prototype
- Pilot · first production
- Scaling production
- Operations · field rollout
- Going global · localizing
- M&A · integration
- Restructuring
Operations · field rollout Five leading pharmaceutical customers and repeat deployments disclosed, with funding raised for further site expansion
- 2026-01-29 The company officially announced that it serves five leading pharmaceutical companies and that repeat deployments are driving growth. Source
Roles often seen at this stage Field, integration & service · Robot software, AI & vision · Quality, regulatory & clinical
Companies at the same stage → · Same stage in other industries →
- It is headquartered in London, with sites in Cambridge and Newton (Massachusetts) in the US and Babenhausen in Germany (company website).
- In January 2026 it raised a USD 45 million Series C led by Dimension, and says its customers include five of the top global pharmaceutical companies (Pulse 2.0, R&D World).
- In a collaboration with CellVoyant announced in January 2026, it said stem cell cardiomyocyte differentiation yield rose by up to 8 times and cell derivation costs fell by more than 85% (company announcement).
Decisions within a year
- It said Series C funds will go to global deployment for pharma, biotech and research institutions, upgrading its data platform and closed-loop experiment software, and expanding engineering, product and customer success teams.
- It said it has formed a strategic partnership with Danaher to integrate Molecular Devices and Beckman Coulter Life Sciences instruments, reagents and software into the LINQ platform (January 2026).
- In an NVIDIA GTC Berlin presentation on October 21, 2026, it was introduced as a collaborating organization connecting NVIDIA Nemotron-based science agents to LINQ automated labs.
People they will look for
- Lab automation software engineers — LINQ orchestration, AI agent integration and closed-loop experiment features
- Automation application scientists — designing genomics, cell biology, analytical and screening workflows for customer experiments
- Customer success and field service engineers — installation, validation and operations support at pharma sites with repeat deployments
For hiring managers
People who know both lab automation and bio data are sought at the same time by Korean biologics contract manufacturers and drug developers and by the Korean entities of global life science instrument companies. With deployments widening now, it is better to secure application scientists and field engineers first.
For job seekers
Hands-on experience building and running liquid handlers or automated work cells in pharma or biotech labs, and experience handling experimental data in Python, are what this company values most right now.
An analysis written from public sources. Sources: Automata website and company overview (sites), Pulse 2.0 2026-01-30 (Series C, five top pharma companies, use of funds, Danaher partnership), R&D World 2026-02-10 (Series C, Danaher, SLAS 2026), Automata 2026-01-13 (CellVoyant collaboration results), Automata 2026-10-21 (NVIDIA GTC Berlin).
Roles hiring now
Skills asked for most
Open jobs
Banseog checks official company careers pages every day. A job is marked closed only when the official page returns a removal (404 or 410).